Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase

Qingming Fang, Natalia A. Loktionova, Robert C. Moschel, Sahar Javanmard, Gary T. Pauly, Anthony Pegg

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT) is an important source of resistance to some therapeutic alkylating agents and attempts to circumvent this resistance by the use of hAGT inhibitors have reached clinical trials. Several human polymorphisms in the MGMT gene that encodes hAGT have been described including L84F and the linked double alteration I143V/K178R. We have investigated the inactivation of these variants and the much rarer variant W65C by O6-benzylguanine, which is currently in clinical trials, and a number of other second generation hAGT inhibitors that contain folate derivatives (O4-benzylfolic acid, the 3′ and 5′ folate esters of O6-benzyl-2′-deoxyguanosine and the folic acid γ ester of O6-(p-hydroxymethyl)benzylguanine). The I143V/K178R variant was resistant to all of these compounds. The resistance was due solely to the I143V change. These results suggest that the frequency of the I143V/K178R variant among patients in the clinical trials with hAGT inhibitors and the correlation with response should be considered.

Original languageEnglish (US)
Pages (from-to)618-626
Number of pages9
JournalBiochemical Pharmacology
Volume75
Issue number3
DOIs
StatePublished - Feb 1 2008

Fingerprint

Folic Acid
Clinical Trials
Esters
Deoxyguanosine
Alkylating Agents
Polymorphism
DNA Repair
Repair
Genes
Derivatives
Acids
DNA
DNA alkyltransferase
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Fang, Qingming ; Loktionova, Natalia A. ; Moschel, Robert C. ; Javanmard, Sahar ; Pauly, Gary T. ; Pegg, Anthony. / Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase. In: Biochemical Pharmacology. 2008 ; Vol. 75, No. 3. pp. 618-626.
@article{9c717af846f0453abf1ce3f4a606e8e7,
title = "Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase",
abstract = "The human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT) is an important source of resistance to some therapeutic alkylating agents and attempts to circumvent this resistance by the use of hAGT inhibitors have reached clinical trials. Several human polymorphisms in the MGMT gene that encodes hAGT have been described including L84F and the linked double alteration I143V/K178R. We have investigated the inactivation of these variants and the much rarer variant W65C by O6-benzylguanine, which is currently in clinical trials, and a number of other second generation hAGT inhibitors that contain folate derivatives (O4-benzylfolic acid, the 3′ and 5′ folate esters of O6-benzyl-2′-deoxyguanosine and the folic acid γ ester of O6-(p-hydroxymethyl)benzylguanine). The I143V/K178R variant was resistant to all of these compounds. The resistance was due solely to the I143V change. These results suggest that the frequency of the I143V/K178R variant among patients in the clinical trials with hAGT inhibitors and the correlation with response should be considered.",
author = "Qingming Fang and Loktionova, {Natalia A.} and Moschel, {Robert C.} and Sahar Javanmard and Pauly, {Gary T.} and Anthony Pegg",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.bcp.2007.09.022",
language = "English (US)",
volume = "75",
pages = "618--626",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "3",

}

Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase. / Fang, Qingming; Loktionova, Natalia A.; Moschel, Robert C.; Javanmard, Sahar; Pauly, Gary T.; Pegg, Anthony.

In: Biochemical Pharmacology, Vol. 75, No. 3, 01.02.2008, p. 618-626.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential inactivation of polymorphic variants of human O6-alkylguanine-DNA alkyltransferase

AU - Fang, Qingming

AU - Loktionova, Natalia A.

AU - Moschel, Robert C.

AU - Javanmard, Sahar

AU - Pauly, Gary T.

AU - Pegg, Anthony

PY - 2008/2/1

Y1 - 2008/2/1

N2 - The human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT) is an important source of resistance to some therapeutic alkylating agents and attempts to circumvent this resistance by the use of hAGT inhibitors have reached clinical trials. Several human polymorphisms in the MGMT gene that encodes hAGT have been described including L84F and the linked double alteration I143V/K178R. We have investigated the inactivation of these variants and the much rarer variant W65C by O6-benzylguanine, which is currently in clinical trials, and a number of other second generation hAGT inhibitors that contain folate derivatives (O4-benzylfolic acid, the 3′ and 5′ folate esters of O6-benzyl-2′-deoxyguanosine and the folic acid γ ester of O6-(p-hydroxymethyl)benzylguanine). The I143V/K178R variant was resistant to all of these compounds. The resistance was due solely to the I143V change. These results suggest that the frequency of the I143V/K178R variant among patients in the clinical trials with hAGT inhibitors and the correlation with response should be considered.

AB - The human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hAGT) is an important source of resistance to some therapeutic alkylating agents and attempts to circumvent this resistance by the use of hAGT inhibitors have reached clinical trials. Several human polymorphisms in the MGMT gene that encodes hAGT have been described including L84F and the linked double alteration I143V/K178R. We have investigated the inactivation of these variants and the much rarer variant W65C by O6-benzylguanine, which is currently in clinical trials, and a number of other second generation hAGT inhibitors that contain folate derivatives (O4-benzylfolic acid, the 3′ and 5′ folate esters of O6-benzyl-2′-deoxyguanosine and the folic acid γ ester of O6-(p-hydroxymethyl)benzylguanine). The I143V/K178R variant was resistant to all of these compounds. The resistance was due solely to the I143V change. These results suggest that the frequency of the I143V/K178R variant among patients in the clinical trials with hAGT inhibitors and the correlation with response should be considered.

UR - http://www.scopus.com/inward/record.url?scp=37849035142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849035142&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2007.09.022

DO - 10.1016/j.bcp.2007.09.022

M3 - Article

C2 - 17996846

AN - SCOPUS:37849035142

VL - 75

SP - 618

EP - 626

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 3

ER -